Diabetic retinopathy

This trial tests whether giving anti-VEGF injections 3, 7, or 14 days before surgery makes a difference for people with proliferative diabetic retinopathy, a complication of diabetes that causes abnormal blood vessels in the eye. Participants are randomly assigned to one of three…

This trial is testing MYL-1701P, a proposed biosimilar to the existing eye medication Eylea, in people with diabetic macular edema who have already completed an earlier study with the same drug. The goal is to see if continued treatment with MYL-1701P is safe and effective over a…

This trial investigates whether adding a dexamethasone implant (Ozurdex) to standard aflibercept (Eylea) injections can better control diabetic macular edema that has not responded to anti-VEGF therapy alone. Adults with persistent retinal swelling will receive either the combina…

This study tests the safety of an experimental eye injection called ONS-5010 (bevacizumab) in people with vision loss from wet age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion. Participants receive the injection and are monitored for side…

This trial tests an investigational drug called BAT5906, given as an eye injection, for people with diabetic macular edema—a condition where fluid builds up in the retina and blurs vision. The study compares two doses (2.5 mg and 4 mg) given multiple times to see which works best…

This study tests whether ketorolac, an anti-inflammatory eye drop, can reduce inflammation in the eyes of people with diabetic retinopathy and slow the disease. About 164 adults with type 2 diabetes will use either the active drop or a placebo for up to 3 years. Researchers will …

This study tests whether injections of ranibizumab, a drug that blocks abnormal blood vessel growth, can help clear bleeding inside the eye in people with diabetes. The bleeding, called diabetic vitreous hemorrhage, can blur or block vision. Participants receive the injection and…

This completed trial tested whether daily omega-3 fish oil supplements can help maintain healthy blood vessels in the eyes of adults with type 1 diabetes. 82 participants took either a 1000 mg omega-3 capsule or a placebo for the study, with regular eye exams to monitor retinal c…

This study examines how well a biosimilar (a lower-cost copy) of the drug ranibizumab works for diabetic macular edema, a condition that causes vision loss in people with diabetes. Researchers will review medical records of 60 adults who received at least one injection of the bio…

This study tests an experimental drug called RO7446603, given alone or with existing medications (aflibercept or faricimab), for people with diabetic macular edema—a condition that causes vision loss due to diabetes. The trial has two parts: an early safety phase (Phase I) and a …

This study tests a drug called faricimab (VABYSMO) in people with diabetic macular edema, a condition where diabetes causes fluid buildup in the center of the retina, leading to vision loss. Participants receive injections of faricimab into the eye every four weeks. The goal is t…

This early study tested a new eye injection called ASKG712 in 10 people with diabetic macular edema, a condition where fluid builds up in the retina and blurs vision. The drug targets two proteins that cause leakage and abnormal blood vessel growth. The main goal was to check saf…

This study tested an oral medication called APX3330 in 103 adults with moderate to severe diabetic retinopathy, a leading cause of vision loss. The pill aims to reduce inflammation and low-oxygen stress in the eye. Researchers measured whether the drug could improve the severity …

This study tested a new eye implant called PER-001 in 27 people with diabetic retinopathy, a diabetes complication that can damage vision. The implant is placed inside the eye and releases medication over time. The main goal was to check safety and how well people tolerate it, lo…

This study tested a pre-filled syringe containing a high dose (8 mg) of the drug aflibercept for two eye conditions: diabetic macular edema and wet age-related macular degeneration. The main goal was to see if retina specialists could prepare and inject the drug easily and safely…

This study tested a new eye medication called PRO-169 against a standard drug (ranibizumab) for people with diabetic macular edema, a condition that causes vision loss in people with diabetes. About 509 adults with diabetes took part, receiving injections into the eye over one ye…

This study tested an eye injection called tarcocimab in 255 people with diabetic retinopathy, a diabetes complication that can damage vision. Participants received either the drug or a sham (fake) injection. The goal was to see if the drug improves the severity of the disease and…

This phase 2 trial tested a new drug called vamikibart, given as an eye injection, for people with diabetic macular edema—a condition where diabetes causes fluid buildup in the center of the retina, leading to vision loss. The study involved 394 participants and compared vamikiba…

This study tested OCS-01, a steroid eye drop, in 552 people with diabetic macular edema (DME), a condition where fluid builds up in the eye and blurs vision. Participants used the drops several times daily for up to a year. The goal was to see if the drops improve vision and redu…

This study tested whether a steroid eye drop called OCS 01 can improve vision in people with diabetic macular edema, a common cause of vision loss in diabetes. Over 400 participants used the drops several times daily for a year. The goal was to see if this non-invasive treatment …

This study tested whether a form of vitamin B6 called pyridoxamine can improve the health of small blood vessels in people with type 2 diabetes. The researchers gave 40 participants either pyridoxamine or a placebo for a period, then switched treatments to compare effects. They m…

This study tested the safety and effectiveness of brolucizumab, a drug injected into the eye, for treating diabetic macular edema (DME) in 66 Indian patients. DME is a complication of diabetes that can cause vision loss. The study aimed to see how well the drug works in real-worl…

This study looked at whether faricimab injections can help people with diabetic retinopathy, a diabetes-related eye disease. Over 12 months, 60 patients received the treatment and doctors measured changes in the back of the eye. The goal was to see if the drug could reduce abnorm…

This phase 3 trial tested a small, refillable implant placed in the eye that continuously releases the drug ranibizumab to control diabetic retinopathy. The study enrolled 174 people with moderate-to-severe non-proliferative diabetic retinopathy but without swelling in the center…

This study tested whether a higher dose (8 mg) of the drug aflibercept, given every 16 weeks, works as well as the standard dose (2 mg) given every 8 weeks for Chinese people with diabetic macular edema (DME), a diabetes-related eye condition that causes vision problems. 333 part…

This study tested a drug called faricimab in 179 people with non-proliferative diabetic retinopathy, a condition where diabetes damages blood vessels in the eye. The goal was to see if the drug could improve blood flow in the retina over 48 weeks. Participants received either mon…

This early-phase trial tested an investigational eye injection called OLN324 in 164 adults with either wet age-related macular degeneration (AMD) or diabetic macular edema (DME). The main goal was to check safety and how the drug moves in the body, with a preliminary look at whet…

This study tested whether levodopa, a drug used for Parkinson's disease, can help people with diabetes who have early signs of eye damage (diabetic retinopathy). The goal was to find the best dose and understand how it works to improve the retina's electrical signals. 230 adults …

This study looked at 83 people with diabetes and early-stage eye disease. It compared having laser treatment in one session versus four sessions to see which approach better controls the disease and reduces the risk of swelling in the center of the eye. The main goal was to measu…

This study looked at the long-term safety of faricimab, a medicine injected into the eye, for people with diabetic macular edema (DME). About 1,500 patients who had completed earlier studies received faricimab at personalized intervals. The main goal was to track side effects, no…

This small Phase 2 study tested INV-102 eye drops in 19 people with diabetic macular edema, a swelling in the back of the eye caused by diabetes. Participants used the drops daily for 8 to 12 weeks. The goal was to see if the drops could improve retinal health and reduce swelling…

This study tested a herbal extract called Nuvastatic in 100 adults with type 2 diabetes who have early-stage diabetic retinopathy (eye damage). The goal was to see if it can safely slow the disease and improve vision. Participants received either the extract or a placebo, and res…

This study looked at whether taking omega-3 supplements for 6 months can improve blood flow in the eyes of people with mild to moderate diabetic retinopathy, a common diabetes complication. Researchers measured tiny blood vessels in the retina using a special camera. The goal was…

This study tested whether aflibercept injections into the eye can improve areas of poor blood flow in the retina of people with diabetic retinopathy. 38 adults with nonproliferative diabetic retinopathy received the treatment. The goal was to see if the drug could reduce the risk…

This study tested a new drug called EYE103, given as an injection into the eye, for people with diabetic macular edema (DME) or wet age-related macular degeneration (NVAMD). The trial had two parts: first, checking safety at increasing doses in about 12 people, then comparing two…

This completed Phase 4 trial tested whether adding a second drug (B55R2) to standard treatment (B55R1) works better for people with non-proliferative diabetic retinopathy, an early stage of diabetic eye disease. 52 adults with mild to severe disease took either the combination or…

This completed Phase 4 study tested how much of the drug aflibercept gets into the bloodstream when a high dose (8 mg) is injected into both eyes of adults with diabetic macular edema or wet age-related macular degeneration. Fifty-one participants received the injections and had …

This phase 2a trial tested a new biologic drug called AG-73305, given as an injection into the eye, in 25 adults with diabetic macular edema (DME), a common cause of vision loss in people with diabetes. The study aimed to check the drug's safety and how well it works over 6 month…

This Phase II trial tested whether adding vamikibart to the standard treatment ranibizumab improves vision more than ranibizumab alone in people with diabetic macular edema. 187 participants received injections into the eye over 76 weeks. The study is complete, and results will s…

This study tested whether an eye injection called brolucizumab works as well as laser treatment for people with proliferative diabetic retinopathy, a serious eye condition caused by diabetes. 689 participants received either the injection or laser, and researchers measured vision…

This study tested an experimental drug called RZ402 in 94 people with diabetic macular edema, a condition that causes vision loss in people with diabetes. The goal was to see if the drug is safe and can reduce swelling in the retina and improve eyesight compared to a placebo. Par…

This study tested whether a steroid implant (Ozurdex) or anti-VEGF injections (Avastin, Lucentis, or Eylea) work better to prevent worsening of diabetic macular edema after cataract surgery. Sixteen adults with diabetes and pre-existing eye swelling received one treatment before …

This study tested the safety of aflibercept, an already-approved eye injection, in 100 Indian adults with diabetic macular edema (DME). Participants received injections every 4 weeks for 5 months, then every 8 weeks for a total of 48 weeks. The main goal was to track any side eff…

This phase 2 trial tested a new way to deliver dexamethasone directly to the back of the eye using tiny microspheres (OXU-001) compared to the standard Ozurdex implant. The study enrolled only 3 adults with diabetic macular edema to check safety and how well the treatment is tole…

This study is testing a new eye imaging device called the VG200D, which uses advanced technology to take detailed pictures of the eye. Researchers want to see if it works as well as a standard device for measuring parts of the eye in people with glaucoma, retina problems, corneal…

This study tested an artificial intelligence (AI) algorithm to detect diabetic retinopathy and glaucoma from eye photos. Researchers compared the AI's accuracy to that of family doctors and retina specialists. The goal was to see if AI could be a reliable screening tool in primar…

This study tests whether a smartphone-based camera can accurately screen for eye diseases such as diabetic retinopathy, glaucoma, and age-related macular degeneration. About 550 patients will have photos taken with both the smartphone camera and standard equipment. Ophthalmologis…

This study tested whether an AI tool can help eye doctors diagnose four common retinal diseases (diabetic retinopathy, age-related macular degeneration, retinal vein occlusion, and glaucoma) more accurately and quickly. Ten doctors from five hospitals read fundus images both with…

This study tested a software called OPTDR01 that automatically checks retinal images for signs of diabetic retinopathy, a leading cause of vision loss. Researchers enrolled 300 adults with diabetes to see if the tool is easy to use and practical in a clinic setting. The goal is t…

This study tested a new device called CRYSTALSIGHT that uses eye-tracking and artificial intelligence to monitor macular diseases like age-related macular degeneration and diabetic retinopathy. Twenty participants used the device at home to see if it could accurately track eye mo…

This study tested a new imaging device called OCT angiography (OCTA) that takes 3D pictures of blood vessels in the back of the eye without needing dye injections. Researchers compared OCTA images to standard dye-based imaging in 88 people with retinal blood vessel problems or no…

This study compared two ways to control pain during laser treatment for diabetic retinopathy: a numbing injection around the eye versus standard numbing eye drops. Fifty adults with diabetes were split into two groups to receive either the injection or a sham injection with drops…

This study tested a nursing intervention designed to help patients relax and feel more comfortable during diabetic retinal laser surgery. 136 adults received either standard care or extra support including guided breathing, clear communication, and reassurance. The goal was to se…

This study tested four different ways of giving dilating eye drops to 84 diabetic patients who needed eye exams for diabetic retinopathy. The goal was to find which method works best to get the pupil large enough for a good exam. Researchers measured pupil size and watched for si…

This study tested whether playing slow tempo music before and during an eye injection (intravitreal injection) can reduce anxiety and pain. 144 adults took part, with half listening to music and the other half receiving standard care. Researchers measured anxiety using saliva tes…

This study tests a microscope that has an OCT scanner built directly into it, allowing surgeons to take detailed cross-sectional images of the eye during surgery. The goal is to see if this setup is practical and whether the extra visual information helps guide surgical decisions…

This completed study observed 572 patients with neovascular age-related macular degeneration or diabetic macular edema who were already receiving brolucizumab injections. Researchers collected routine medical data to see how well the drug resolved fluid in the eye and improved vi…

This study reviews published research on artificial intelligence models that analyze retinal images to predict how well patients with diabetic macular edema will respond to treatments like anti-VEGF injections or laser therapy. By evaluating the accuracy of these AI tools, the re…

This trial tests a new device called P200TxE that takes detailed images of the back of the eye. Researchers want to see how well it captures images in people with retinal diseases like glaucoma or macular degeneration. The study involves adults aged 22 and older who have been dia…

This study tested whether artificial intelligence (AI) can help doctors detect retinal diseases from ultra-widefield eye images. 462 images were read by four eye doctors with different experience levels, both with and without AI assistance. The goal was to see if AI improves accu…

This study tested whether doctors could safely and correctly use a new prefilled syringe (SCD411) for eye injections. It included 33 adults with wet age-related macular degeneration, retinal vein occlusion, diabetic macular edema, or diabetic retinopathy. The main goal was to see…

This study looked at whether monitoring moderate diabetic retinopathy (an eye condition caused by diabetes) through tele-expertise (remote specialist review) works as well as the usual in-person eye doctor visits. Researchers followed 97 patients with diabetes and moderate retino…

This study looked at 60 adults with type 2 diabetes and early diabetic eye disease. Researchers used a special eye scan (OCTA) to measure blood flow in the retina. The goal was to find which scan details best predict if the disease will get worse and threaten sight. No treatment …

This study tested four different approaches to find and treat eye diseases like cataracts, glaucoma, and diabetic retinopathy in communities in Nepal. Over 87,000 people aged 50 and older took part. The goal was to see which method—comprehensive screening, cataract camps, communi…

This study looked at how much of a burden patients feel from repeated anti-VEGF eye injections for three different eye diseases: wet age-related macular degeneration, retinal vein occlusion, and diabetic macular edema. Researchers surveyed 393 patients about their treatment burde…

This pilot study tested whether a patient navigator—a person who helps coordinate medical care—could increase eye exam rates in 35 adults with diabetes who were at high risk for blindness. Participants met with a navigator quarterly to overcome barriers to care. The study measure…

This study measured the thickness of the conjunctiva and Tenon's capsule (outer eye layers) in 736 people with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME), and in healthy volunteers of similar age. Researchers used a special eye scanner (SD…

This study measured three substances in the blood (endocan, alarin, and galanin-like peptide) in people with and without diabetic retinopathy, an eye complication of diabetes. Researchers compared these levels across different stages of the disease and looked at how they relate t…

This study looked at 360,000 French patients who received eye injections for conditions like age-related macular degeneration. The goal was to find out how often a serious eye infection called endophthalmitis happens within 28 days after the injection. Researchers analyzed data f…

This study tested whether people with diabetes can use a smartphone game to monitor their vision at home, instead of always going to the clinic. 55 participants at high risk for diabetic retinopathy played vision games on their phones for 6 months. The goal was to see if people w…

This study examined whether certain genes are linked to a severe form of diabetic eye disease called proliferative diabetic retinopathy (PDR). Researchers analyzed DNA from 302 people with type 2 diabetes, some with PDR and some without. The goal was to find genetic markers that …

This study tested whether artificial intelligence (AI) can help doctors better predict how diabetic retinopathy (an eye disease from diabetes) will progress. Over 3,000 adults with diabetes were followed for about 2 years. The goal was to create a smarter system that uses eye ima…

This completed study used a special eye scan called OCTA to look at tiny blood vessels in the retina of 200 people with type 2 diabetes who had no signs of eye disease on a standard exam. The goal was to see if the duration of diabetes affects these vessels. The findings could he…

This study looked at 202 adults with type 2 diabetes and early-stage diabetic eye disease (non-proliferative diabetic retinopathy). Researchers used non-invasive eye scans to find markers that could predict if the disease would get worse or lead to sight-threatening problems. The…

This study looked at whether specific features on eye imaging scans can predict how well a person with diabetic macular edema will respond to treatment. Researchers analyzed images from 32 participants to find patterns linked to better or worse outcomes. The goal is to help docto…

This study looked at over 550,000 people who received Eylea® injections for eye conditions to find out how often retinal vasculitis (a rare eye inflammation) occurs. Researchers used a large US registry and medical records to confirm cases. The goal was to better understand the s…

This completed study analyzed data from nearly 290,000 patients who received aflibercept (Eylea) injections for various retinal diseases. The goal was to estimate how often retinal vasculitis (inflammation of blood vessels in the eye) occurs in real-world clinical practice. Resea…

This study looked back at the medical records of 400 people with neovascular glaucoma, a severe eye condition. Researchers wanted to see how it relates to other diseases, lifestyle factors, and inflammation. The goal is to better understand the condition and guide future treatmen…